NanoViricides, Inc. is a development-stage company that is creating special-purpose nanomaterials for antiviral therapy. The company's novel nanoviricide class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them.
It is developing clinical candidates for the treatment of COVID-19 disease caused by SARS-CoV-2 coronavirus. Its other lead drug candidate is NV-HHV-101 with its first indication as dermal topical cream for the treatment of shingles rash. In addition, the company has several antiviral programs in various pre-clinical stages.